Flibanserin attenuates L-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease

Journal of Neural Transmission

Volumn 118, Issue 12, 2011, Pages 1727-1732

  Gerlach, Manfred ^a   Beck, Jürgen ^b   Riederer, Peter ^a   Van Den Buuse, Maarten ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Lancier Monitoring GmbH   (Germany)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

6 Hydroxydopamine; Buspirone; Flibanserin; l DOPA induced dyskinesia; Parkinson therapy; Rat; Serotonin 5 HT 1A agonists

Indexed keywords

BENSERAZIDE; BUSPIRONE; FLIBANSERIN; LEVODOPA; LEVODOPA METHYL ESTER; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DYSKINESIA; LEVODOPA INDUCED DYSKINESIA; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL LATERALITY; LEVODOPA; MALE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPIC MOVEMENT DISORDER; TIME FACTORS;

EID: 84855207787     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0570-9     Document Type: Article

References (37)

1. JT Apter LA Allen 1999 Buspirone: future directions J Clin Psychopharmacol 19 86 93 9934947 10.1097/00004714-199902000-00014 1:CAS:528:DyaK1MXpvFSjsg%3D%3D (Pubitemid 29047335)
2. R Arai K Horiike Y Hasegawa 1998 Dopamine-degrading activity of monoamine oxidase in locus coeruleus and dorsal raphe nucleus neurons. A histochemical study in the rat Neurosci Lett 250 41 44 9696061 10.1016/S0304-3940(98)00429-7 1:CAS:528:DyaK1cXjvFOgsbo%3D (Pubitemid 28341772)
3. F Bibbiani JD Oh TN Chase 2001 Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 1829 1834 11723272 1:CAS:528:DC%2BD38XjvVI%3D (Pubitemid 33096691)
4. V Bonifati E Fabrizio R Cipriani N Vanacore G Meco 1994 Buspirone in levodopa-induced dyskinesias Clin Neuropharmacol 17 73 82 8149361 10.1097/00002826-199402000-00008 1:STN:280:DyaK2c7pvFGntQ%3D%3D (Pubitemid 24046709)
5. F Borsini K Evans K Jason F Rohde B Alexander S Pollentier 2002 Pharmacology of flibanserin CNS Drug Rev 8 117 142 12177684 10.1111/j.1527-3458. 2002.tb00219.x 1:CAS:528:DC%2BD38Xmsl2iurc%3D (Pubitemid 34874381)
6. JM Brotchie J Lee K Venderova 2005 Levodopa-induced dyskinesia in Parkinson's disease J Neural Transm 112 359 391 15614429 10.1007/s00702-004- 0251-7 1:CAS:528:DC%2BD2MXhsVOmtrk%3D (Pubitemid 40868050)
7. RJ Carey 1986 Relationship of changes in spontaneous motor activity to spontaneous circling in rats with unilateral 6-hydroxydopamine lesions Exp Neurol 92 591 600 3086112 10.1016/0014-4886(86)90301-8 1:CAS:528: DyaL28XksVSntrg%3D (Pubitemid 16074638)
8. RJ Carey 1991 Chronic l-dopa treatment in the unilateral 6-OHDA rat-evidence for behavioral sensitization and biochemical tolerance Brain Res 568 205 214 1814568 10.1016/0006-8993(91)91399-L 1:CAS:528:DyaK38XpvFWrug%3D%3D
9. M Carta M Carlsson D Kirik A Björklund 2007 Dopamine released from 5-HT terminals is the cause of l-dopa-induced dyskinesia in parkinsonian rats Brain 130 1819 1833 17452372 10.1093/brain/awm082 (Pubitemid 47343795)
10. MA Cenci 2007 Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia Trends Neurosci 30 236 243 17400300 10.1016/j.tins.2007.03.005 1:CAS:528:DC%2BD2sXkslent7s%3D (Pubitemid 46654236)
11. MA Cenci CS Lee A Björklund 1998 l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur J Neurosci 10 2694 2706 9767399 10.1046/j.1460-9568. 1998.00285.x 1:STN:280:DyaK1M7ksFKrsA%3D%3D (Pubitemid 28362576)
12. DR Cooper C Marrel B Testa H van de Waterbeemd N Quinn P Jenner CD Marsden 1984 l-Dopa methyl ester: a candidate for chronic systemic delivery of l-Dopa in Parkinson's disease Clin Neuropharmacol 7 89 98 6704979 10.1097/00002826-198403000-00005 1:CAS:528:DyaL2cXhs1yitbg%3D (Pubitemid 14138570)
13. A Dekundy M Lundblad W Danysz MA Cenci 2007 Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behav Brain Res 179 76 89 17306893 10.1016/j.bbr.2007.01.013 1:CAS:528:DC%2BD2sXjsVegur8%3D (Pubitemid 46441485)
14. KB Dupre KL Eskow B Negron C Bishop 2007 The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rats Brain Res 1158 135 143 17553470 10.1016/j.brainres.2007.05.005 1:CAS:528:DC%2BD2sXotVWltrk%3D (Pubitemid 47068412)
15. 1A agonist buspirone reduces the expression and delopment of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy Pharmacol Biochem Behav 87 306 314 17553556 10.1016/j.pbb.2007.05.002 1:CAS:528: DC%2BD2sXotlWlt74%3D (Pubitemid 47101876)
16. KL Eskow KB Dupre CJ Barnum SO Dickinson JY Park C Bishop 2009 The role of the dorsal raphe nucleus in the development, expression, and treatment of l-dopa-induced dyskinesia in hemiparkinsonian rats Synapse 63 610 620 19309758 10.1002/syn.20630 1:CAS:528:DC%2BD1MXmsFSqu7w%3D
17. SH Fox AE Lang JM Brotchie 2006 Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase Ila clinical studies: keys to success and roads to failure Mov Disord 21 1578 1594 16874752 10.1002/mds.20936 (Pubitemid 44742184)
18. M Gerlach P Riederer 1996 Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man J Neural Transm 103 987 1041 9013391 10.1007/BF01291788 1:CAS:528:DyaK28XntVKku7Y%3D (Pubitemid 26383833)
19. M Gerlach M van den Buuse C Blaha D Bremen P Riederer 2004 Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine- lesioned rat Naunyn Schmiedeberg's Arch Pharmacol 370 388 394 10.1007/s00210-004-0984-8 1:CAS:528:DC%2BD2cXps1Wqurs%3D (Pubitemid 40022459)
20. B Henry AR Crossman JM Brotchie 1999 Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat Exp Neurol 155 204 220 10072296 10.1006/exnr.1998.6996 1:CAS:528: DyaK1MXhs1Smu7o%3D (Pubitemid 29124714)
21. MM Iravani MJ Jackson M Kuoppamaki LA Smith P Jenner 2003 3, 4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine- treated primates J Neurosci 23 9107 9115 14534244 1:CAS:528:DC%2BD2cXhvF2isb0%3D (Pubitemid 37243811)
22. JJ Jankovic 2005 Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Mov Disord 20 Suppl. 11 S11 S16 15822109 10.1002/mds.20458 (Pubitemid 40846906)
23. P Jenner 2008 Molecular mechanisms of l-DOPA-induced dyskinesia Nat Rev Neurosci 9 665 677 18714325 10.1038/nrn2471 1:CAS:528:DC%2BD1cXhtVSjurvP
24. EL Lane SC Cheetham P Jenner 2006 Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol 197 284 290 16005456 10.1016/j.expneurol.2005.06.006 1:CAS:528:DC%2BD28XksVKgsQ%3D%3D (Pubitemid 43077136)
25. M Lundblad M Andersson C Winkler D Kirik N Wierup MA Cenci 2002 Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur J Neurosci 15 120 132 11860512 10.1046/j.0953-816x.2001.01843.x 1:STN:280:DC%2BD387ktFynug%3D%3D (Pubitemid 35478015)
26. M Lundblad B Picconi H Lindgren MA Cenci 2004 A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function Neurobiol Dis 16 110 123 15207268 10.1016/j.nbd.2004.01.007 1:CAS:528:DC%2BD2cXjs1altbw%3D (Pubitemid 38569802)
27. 1A agonist J Pharmacol Exp Ther 271 875 883 7965808 1:CAS:528:DyaK2MXisVyjsrs%3D (Pubitemid 24377777)
28. BA McMillen RT Matthews MK Sanghera PD Shepard DC German 1983 Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone J Neurosci 3 733 738 6131948 1:CAS:528:DyaL3sXktVSnsLg%3D (Pubitemid 13114090)
29. T Müller H Russ 2006 Levodopa, motor fluctuations and dyskinesia in Parkinson's disease Expert Opin Pharmacol 7 1715 1730 10.1517/14656566.7.13.1715
30. T Müller D Woitalla H Russ K Hock DA Haeger 2007 Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease J Neural Transm 114 1023 1026 17417738 10.1007/s00702-007-0718-4 (Pubitemid 47106454)
31. A Nadjar CR Gerfen E Bezard 2009 Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol 87 1 9 18938208 10.1016/j.pneurobio.2008.09.013 1:CAS:528: DC%2BD1MXmvVartw%3D%3D
32. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, San Diego
33. D Rylander M Parent SS O'Sullivan S Dovero AJ Lees E Bezard L Descarries MA Cenci 2010 Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann Neurol 68 619 628 20882603 10.1002/ana.22097 1:CAS:528:DC%2BC3cXhsFOnsrnE
34. J Schwarz K Strecker S Ohm J Beck 2005 Flibanserin but not buspirone reduces levodopa-induced dyskinesia in RGS9 deficient mice J Neurol Sci 238 Suppl. 1 369
35. DP Taylor 1988 Buspirone, a new approach to the treatment of anxiety FASEB J 2 2445 2452 2836252 1:CAS:528:DyaL1cXmtVCitbY%3D
36. U Ungerstedt GW Arburthnott 1970 Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions in the nigrostriatal dopamine system Brain Res 24 485 493 5494536 10.1016/0006-8993(70)90187-3 1:STN:280:DyaE3M%2Fotl2msA%3D%3D
37. BY Zeng MM Iravani MJ Jackson S Rose A Parent P Jenner 2010 Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol Dis 40 599 607 20713157 10.1016/j.nbd.2010.08.004 1:CAS:528:DC%2BC3cXhtlSnurjP